Fabian Birzele

Fabian Birzele

Auto-generated profile, based on publicly available information

Fabian Birzele

Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, F. Hoffmann-La-Roche AG, 4070 Basel, Switzerland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2020 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
SBSolveig Badillo
Solveig Badillo
BBBalazs Banfai
Balazs Banfai
FBFabian Birzele
Fabian Birzele
IDIakov I. Davydov
Iakov I. Davydov
LHLucy Hutchinson
Lucy Hutchinson
JZJitao David Zhang
Jitao David Zhang
In the last few years, machine learning (ML) and artificial intelligence have seen a new wave of publicity fueled by the huge and ever‐increasing amount of data and computational power as well as the discovery of improved learning algorithms. However, the idea of a computer learning some abstract concept from data and applying them to yet unseen situations is not new and has been around at least since the 1950s. Many of these basic principles are very familiar to the pharmacometrics and clinical pharmacology community. In this paper, we want to introduce the foundational ideas of ML to this community such that readers obtain the essential tools they need to understand publications on the topic. Although we will not go into the very details and theoretical background, we aim to point readers to relevant literature and put applications of ML in molecular biology as well as the fields of pharmacometrics and clinical pharmacology into perspective.

8 June 2022 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
MDMorgane Denis
Morgane Denis
CGChloé Grasselly
Chloé Grasselly
PCPierre-Antoine Choffour
Pierre-Antoine Choffour
Anne WierinckxAnne Wierinckx
Anne Wierinckx
DMDoriane Mathé
Doriane Mathé
CDCharles Dumontet
Charles Dumontet
Antibodies targeting PD-1 and PD-L1 have produced durable responses in a subset of patients with cancer. However, a majority of these patients will ultimately relapse due to acquired resistance. To explore the underlying mechanisms of this secondary resistance, we developed five syngeneic murine tumor variants with acquired resistance to anti–PD-1 and/or PD-L1 antibodies in vivo. Resistant in vivo models were obtained by serial treatment/reimplantation cycles of the MC38 colorectal, MB49 and MBT2 bladder, and RENCA kidney and TyrNras melanoma models. Tumor immune infiltrates were characterized for wild type and resistant tumors using spectral cytometry and their molecular alterations analyzed using RNA sequencing analyses. Alterations in the tumor immune microenvironment were strongly heterogeneous among resistant models, involving select lymphoid and/or myeloid subpopulations. Molecular alterations in resistant models included previously identified pathways as well as novel candidate genes found to be deregulated in several resistant models. Among these, Serpinf1, coding for pigment epithelial-derived factor (PEDF) was further explored in the MC38 and the MBT2 models. Overexpression of Serpinf1 induced resistance to anti–PD-1 antibodies in the MC38 model, whereas knockdown of Serpinf1 sensitized this model as well as the primarily resistant MBT2 model. Serpinf1 overexpression was associated with increased production of free fatty acids and reduced activation of CD8+ cells, while orlistat, a compound that reduces the production of free fatty acids, reversed resistance to anti–PD-1 therapy. Our results suggest that a panel of syngeneic resistant models constitutes a useful tool to model the heterogeneity of resistance mechanisms encountered in the clinic.

25 May 2023 in Drug Discovery Today
Verified
Journal Article
Closed access
TSThomas Steger-Hartmann
Thomas Steger-Hartmann
AKAnnika Kreuchwig
Annika Kreuchwig
KWKen Wang
Ken Wang
FBFabian Birzele
Fabian Birzele
DDDragomir Draganov
Dragomir Draganov
ARAndreas Rothfuss
Andreas Rothfuss

4 April 2023
Verified
Other
Open access
MDMorgane Denis
Morgane Denis
CGChloé Grasselly
Chloé Grasselly
PCPierre-Antoine Choffour
Pierre-Antoine Choffour
Anne WierinckxAnne Wierinckx
Anne Wierinckx
DMDoriane Mathé
Doriane Mathé
CDCharles Dumontet
Charles Dumontet
Antibodies targeting PD-1 and PD-L1 have produced durable responses in a subset of patients with cancer. However, a majority of these patients will ultimately relapse due to acquired resistance. To explore the underlying mechanisms of this secondary resistance, we developed five syngeneic murine tumor variants with acquired resistance to anti–PD-1 and/or PD-L1 antibodies in vivo. Resistant in vivo models were obtained by serial treatment/reimplantation cycles of the MC38 colorectal, MB49 and MBT2 bladder, and RENCA kidney and TyrNras melanoma models. Tumor immune infiltrates were characterized for wild type and resistant tumors using spectral cytometry and their molecular alterations analyzed using RNA sequencing analyses. Alterations in the tumor immune microenvironment were strongly heterogeneous among resistant models, involving select lymphoid and/or myeloid subpopulations. Molecular alterations in resistant models included previously identified pathways as well as novel candidate genes found to be deregulated in several resistant models. Among these, Serpinf1, coding for pigment epithelial-derived factor (PEDF) was further explored in the MC38 and the MBT2 models. Overexpression of Serpinf1 induced resistance to anti–PD-1 antibodies in the MC38 model, whereas knockdown of Serpinf1 sensitized this model as well as the primarily resistant MBT2 model. Serpinf1 overexpression was associated with increased production of free fatty acids and reduced activation of CD8+ cells, while orlistat, a compound that reduces the production of free fatty acids, reversed resistance to anti–PD-1 therapy. Our results suggest that a panel of syngeneic resistant models constitutes a useful tool to model the heterogeneity of resistance mechanisms encountered in the clinic.

4 April 2023
Verified
Other
Open access
MDMorgane Denis
Morgane Denis
CGChloé Grasselly
Chloé Grasselly
PCPierre-Antoine Choffour
Pierre-Antoine Choffour
Anne WierinckxAnne Wierinckx
Anne Wierinckx
DMDoriane Mathé
Doriane Mathé
CDCharles Dumontet
Charles Dumontet
Supplementary Data from In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 Therapies

4 April 2023
Verified
Other
Open access
MDMorgane Denis
Morgane Denis
CGChloé Grasselly
Chloé Grasselly
PCPierre-Antoine Choffour
Pierre-Antoine Choffour
Anne WierinckxAnne Wierinckx
Anne Wierinckx
DMDoriane Mathé
Doriane Mathé
CDCharles Dumontet
Charles Dumontet
Supplementary Data from In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 Therapies